You could be right. Either way it bodes well for we who remain....

You could be right.  Either way it bodes well for we who remain.
.

Andrew Harrison is sooo faaaar fuuurther across running a business than JC it's not funny.

Yes JC's vision and readiness to punt on Enlitic will hopefully benefit CAJ eventually, and his moves to make overtures to Chinese medical sector a positive for the (patient) holder, yet his other poorly judged, irrational expansionary moves as well as the financial structuring of those have cost us aplenty.

Was always uneasy with the way Conidi allegedly dealt with the founder/ inventor of the 3D printing business a few years back, (I wasn't willing to take up the offered shares in that business), and frankly he came across to me as a bit of a shabby bumbler.  Huge relief that he no longer has a role!

Mr Harrison's rationalisation / repositioning program will salvage a good business and set us up for a steady appreciation, which leads us back to the topic of the thread;  a lot less shareholders we'll be sharing the spoils with in FY 18 and beyond .

While I'm currently a hold, I'm ready to buy more after watching the buyback play out.  (bearing in mind many pundits believe a correction of sorts is due before end 2017, maybe this'll drift then....but my thoughts are probably well flawed and I'm just being an opportunist!)

Initially intended this to be one line response to campjor and tamz, but found myself reflecting on the CAJ journey, and posting those as well.  (thanks for the indulgence )